Clinical Trial Update: CYTALUX Dose Extension Study [Phase 4]

View source ↗

Summary

Phase 4 dose-extension study of CYTALUX by On Target Laboratories; the trial is not yet recruiting and targets lung cancer and ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Ovarian Cancer

Drugs mentioned

• Cytalux (pafolacianine)

Snippet

Sponsor: On Target Laboratories, LLC | Conditions: Cancer in the Lung, Ovarian Cancer | Phase 4 | Status: NOT_YET_RECRUITING